Houston company wins AHA competition for pediatric heart valve design

winner, winner

Houston-based PolyVascular won the American Heart Association’s annual Health Tech Competition. Courtesy of TMC Innovation

Houston-based PolyVascular, which develops minimally invasive solutions for children with congenital heart disease, was named the overall winner of the American Heart Association’s annual Health Tech Competition earlier this month.

The company was founded in 2014 by Dr. Henri Justino and Daniel Harrington and was part of TMCi's 2017 medical device cohort. It is developing the first polymer-based transcatheter pulmonary valve designed specifically for young children, allowing for precise sizing and redilation as the child grows while also avoiding degradation. PolyVascular has completed preclinical studies and is working toward regulatory submissions, an early feasibility study and its first-in-human clinical trial thanks to a recent SBIR grant from the National Heart, Lung, and Blood Institute.

With the new AHA honor, PolyVascular will be invited to join the association’s Center for Health Technology & Innovation Innovators’ Network, which connects entrepreneurs, providers and researchers to share and advance innovation in cardiovascular and brain health.

“This is a tremendous honor for PolyVascular—we’re especially proud to bring hope to families and children living with congenital heart defects,” Justino said in a news release. “Our technology—a minimally invasive valve that can be expanded over time to grow with the child—has the potential to dramatically reduce the need for repeated open-heart surgeries.”

The Health Tech Competition is a live forum for health care innovators to present their digital solutions for treating or preventing cardiovascular diseases and stroke.

Finalists from around the world addressed heart failure, hypertension, congenital heart defects and other issues that exist in cardiovascular, brain and metabolic health. Solutions were evaluated on the criteria of validity, scientific rigor and impact.

The judges included Texas-based Dr. Eric D. Peterson, professor of medicine in the division of cardiology at UT Southwestern Medical Center, and Dr. Asif Ali, clinical associate professor of cardiovascular medicine at the University of Texas Medical School in Houston and director at Cena Research Institute.

According to the American Heart Association, nearly half of U.S. adults live with some form of cardiovascular disease or stroke.

“The American Heart Association plays a pivotal role in advancing innovative care pathways, and we’re excited that our solution aligns with its guidelines and mission,” Justino said in a news release. “It’s time these life-changing technologies reach the youngest patients, just as they already do for adults.”

From Your Site Articles
Six Houston startups — from health tech to aerospace — have moved into the new East End Maker Hub. Image courtesy of East End Maker Hub

New innovation hub grows with the addition of 6 Houston startups

moving in

The East End Maker Hub in Houston's East End District is growing with the recent addition of six startups.

"All of these companies cite the East End Maker Hub's physical innovation infrastructure, customizable spaces, strategic location, and potential collaborators as motivations for moving their operations into the hub," Patrick Ezzell, president of Urban Partnerships Community Development Corp., one of the hub's creators, says in an April 26 news release. "All are in the process of growing their teams and view Houston and, more specifically, the East End as a key resource for human capital heading into the future."

The companies that recently joined the East End Maker Hub are:

  • Alchemy Industrial. The company is a contract manufacturer that uses advanced technologies to develop industrial products for the medical, renewable energy, and drone sectors. Mush Khan, a British-born entrepreneur, established the startup last year.
  • CarbonATM. Led by Frank Zamarron and a group of former NASA engineers, CarbonATM aims to improve monitoring of ambient air quality with a low-cost portable device.
  • Gbowo Inc. This startup, founded in 2020, seeks to help companies reduce the environmental and financial costs of last-mile deliveries through the use of low-speed electrical vehicles. Ganiu Ladejobi is the founder and CEO.
  • Horizon Aeromarine. Established in 2020, the startup develops software and electronics from unmanned aerial and marine vehicles. Laura Sammons and Denver Hopkins are the founders.
  • Parallax 621. Founded by Benjamin Peters and Phillip Lentz, the Parallax 621 tech think tank develops technology based on theoretical physics research.
  • Polyvascular. The startup, established in 2014, makes a polymer-based heart valve for children with congenital heart disease.

The East End Maker Hub, at 6501 Navigation Blvd., is a collaboration between TXRX Labs and Urban Partnerships Community Development that houses crafters, fabricators, and tech manufacturers. TXRX Labs invested $1.25 million in equity to set up the hub. Urban Partnerships Community Development raised $35.75 million in capital to get the project off the ground.

Houston-based PolyVascular has invented a polymer-based heart valve for children with congenital heart disease. Photo courtesy of TMC Innovation

Houston startup with life-saving innovation receives $2M grant

for the children

A $2 million federal grant will enable Houston-based PolyVascular to launch human trials of what it hails as the first polymer-based heart valve for children.

In conjunction with the grant, Dr. Will Clifton has joined the medical device company as chief operating officer. He will oversee the grant as principal investigator, and will manage the company's operations and R&D. Clifton is president and co-founder of Houston-based Enventure, a medical innovation incubator and education hub. He previously was senior director of medical affairs at Houston-based Procyrion, a clinical-stage medical device company.

PolyVascular's Phase II grant came from the Small Business Innovation Research (SBIR) program, which promotes technological projects.

The PolyVascular heart valve will help treat congenital heart disease affecting more than 1 million around the world. PolyVascular plans to launch clinical trials of the valve in children 5 and over within two years.

"Congenital heart disease remains the most common category of birth defect and a leading cause of childhood death in the developed world," reads a March 30 news release from PolyVascular, founded in 2014.

PolyVascular says the valve can be implanted without surgery, and can avoid the use of valve replacements from humans or animals. Those valve replacements are difficult to find and often don't last too long, leading to frequent follow-up surgeries.

"Our aim at PolyVascular is to transform the care of children with congenital heart disease by developing an entirely new generation of valves made of medical-grade polymer devoid of any biological tissue," Dr. Henri Justino, chief medical officer at PolyVascular, says in a release. "The valves in use so far for children have been made of biological tissue. Unfortunately, our immune systems target and destroy this biological tissue, sometimes rapidly, rendering the valve ineffective."

The SBIR grant isn't the only win for PolyVascular in recent years.

In 2019, the startup came away with several honors in the 2019 Texas A&M New Ventures Competition. It won the pitch competition (complete with a $5,000 cash award), and received the Biotex Investment Prize, Amerra Visualization Services Prize, and GOOSE Society Investment Prize.

Also in 2019, PolyVascular, a member of TMCx's 2017 medical device cohort, won in the medical device and health disparities and equity categories at the fifth annual Impact Pediatric Health pitch competition. Additionally, the Southwest National Pediatric Device Consortium granted the company up to $25,000.

Last year, MedTech Innovator, a nonprofit accelerator in the medical technology sector, announced PolyVascular was one of 50 companies chosen to participate in the organization's flagship four-month accelerator program.

"During these uncertain and challenging times, the need for health innovations — specifically those that promise to deliver long-term value to the health care system and patients — is more critical than ever," said Paul Grand, CEO of MedTech Innovator.

Another Houston startup, Vivante Health, also was picked for the MedTech Innovator program. Vivante is a digital health company that helps people address digestive health and wellness.

Spark Biomedical took home first place at the Texas A&M New Ventures Competition. Courtesy of Texas A&M

Houston companies take home big prizes from a Texas A&M startup competition

Big winners

Earlier this month, 16 startups competed in the 2019 Texas A&M New Ventures Competition for more than $350,000 in cash and in-kind services — the largest pool of prizes in the contest's history.

Houston had a huge presence at TNVC this year. Several Houston startups competed in the technology- and science-focused pitch competition, and the top three prizes were claimed by Houstonians. Of the 13 health and life science companies that were named semifinalists, seven were related to the TMC Innovation Institute.

Here are the Houston companies that walked away from the TNVC with cash and/or prizes.

Spark Biomedical

Friendswood-based medical device company Spark Biomedical took home the top prize at TNVC, which came with a $50,000 check. Spark's technology uses a noninvasive neurostimulation treatment for opioid addiction recovery.

"I'm very humbled and grateful," says Daniel Powell, CEO of Spark, in a release. "This award means a lot because Texas A&M is my alma mater. Being back here is fantastic, and this win is a testament to the work we're doing and our dedication to making a difference with this product."

Spark also was recognized with the Southwest Pediatric Device Prize and the Aggie Angel Network Investment Prize. Recently, Spark announced a partnership with another Houston startup, Galen Data.

SurfEllent

Photo via surfellent.com

Coming in at No. 2 overall and receiving a $35,000 prize was Houston-based advanced coating company, SurfEllent. The company, which is based out of the University of Houston's Technology Park, has designed an anti-icing technology that can be used in any type of situation from de-icing cars to aeronautical applications.

SurfEllent was also recently recognized as one of the top three innovators at NASA's 2017 iTech forum, out of 130 entries across the US.

The company also walked away with the TEEX Product Development Center Prize.

Intelligent Implants

Photo by Cody Duty/TMC

Intelligent Implants called Houston home during the 2018 TMCx medical device cohort and still has a presence in town. The company, which created a, implantable wireless device that stimulates bone growth using electrical stimulation, claimed third prize and $25,000.

Last fall, following its success at TMCx, Intelligent Implants was named the "Most Promising Life Science Company" at the 2018 Texas Life Science Forum hosted by the Rice Alliance and BioHouston.

VenoStent

Photo via venostent.com

Another 2018 TMCx medical device cohort member competed at the TNVC and left with fresh funds. VenoStent took fifth place and a $10,000 prize. VenoStent has a device that allows a successful stent implementation on the first try, called the SelfWrap. The device is made from a shape-memory polymer that uses body heat to mold the stent into the vein-artery junction.

VenoStent, which has its headquarters in Nashville, Tennessee, also won the Ramey & Schwaller IP Legal Services Prize.

PolyVascular

Courtesy of TMC Innovation

Houston-based PolyVascular walked away a big winner of multiple prizes. The company, a member of TMCx's 2017 medical device cohort, creates polymeric transcatheter valves for children with congenital heart disease.

PolyVascular won the TNVC pitch competition, which came with a $5,000 prize. The startup also walked away with the Biotex Investment Prize, the Amerra Visualization Services Prize, and the GOOSE Society Investment Prize.

Ictero Medical

Ictero Medical, which operates out of JLABs at TMC, took home several prizes, including the Thomas | Horstemeyer IP Legal Services Prize, the TMC Accelerator Admission Prize, and the Engineering Vice Chancellor Innovation Prize — a new award that came with a $15,000 prize.

Ictero created the CholeSafe System — a minimally invasive device that treats gallstone disease patients in a procedure with "only minimal local anesthesia to defunctionalize the gallbladder without having to remove it," according to the website.

Sun Co. Tracking

Sun Co. Tracking was the other of the two startups to receive the new Engineering Vice Chancellor's Innovation Prize and its own $15,000 prize. The Houston-based company is developing shape memory alloy actuators for solar panels.

"This unique prize is intended to help the awardees access the world-class engineering capabilities at Texas A&M to obtain technical assistance toward solving their most challenging technical problems in product design, manufacturing or testing," says Dr. Balakrishna Haridas, TEES director for technology commercialization and entrepreneurship, in a release.

"These collaborations between the prize winners and Texas A&M Engineering will generate technical data to support on Small Business Innovation Research/grant proposal funding or private capital investments to the company."

GaitIQ

Photo via LinkedIn

GaitIQ is based in San Antonio, but is automatically accepted into TMCx's tenth cohort if they'd like, since the company won the TMC Investment Prize. The company, which created a primary care app that uses artificial intelligence and cloud-based technology, also won sixth place overall and $5,000.

GaitIQ also won the Ark Pharmacies, Inc. Regional Prize, the Hollinden Marketing and Strategists Services Prize, and the Schwegman Lundberg and Woessner IP Legal Services Prize.

Houston-based PolyVascular earned recognition in two categories, as well as nabbing up to $25,000. Courtesy of TMC Innovation

2 TMCx companies leave SXSW with awards and grant money

Med tech

Two Houston companies are walking away from SXSW with awards and grant funds.

PolyVascular, a member of TMCx's 2017 medical device cohort, won the fifth annual Impact Pediatric Health pitch competition's medical device and health disparities and equity categories. Additionally, the Southwest National Pediatric Device Consortium granted the company up to $25,000.

PolyVascular co-founder Henri Justino represented his company in three-minute pitch, and team members Dan Harrington and Kwon Soo Chun were also in attendance.

The company was one of 12 finalists in the competition, which took place on March 8 at SXSW in Austin. Among the judges was Houston doctor, Chester Koh, professor of urology, pediatrics, and OB/GYN at Baylor College of Medicine and Pediatric Urologist at Texas Children's Hospital.

"At the Southwest National Pediatric Device Consortium, we are always looking for the next cutting-edge breakthrough in the world of medical devices," says Koh in a release. "Impact Pediatric Health's reputation for bringing together the leaders in pediatric medical technology innovations makes it the perfect venue to help identify and accelerate the next generation of medical device companies impacting our youngest of patients."

Founded in 2014, PolyVascular produces polymeric transcatheter valves for children with congenital heart disease — the most common birth defect and number one cause of infant mortality in the developed world. The company's goal is to reduce that number of infant deaths by introducing a higher quality of valves.

Meanwhile, VastBiome, a 2018 biodesign TMCx company, received a $1,000 grant and is now one of two finalists for the San Francisco-based Illumina Accelerator program. The company works with scientists with ongoing clinical trials focusing on the microbiome as it pertains to therapy.

Another TMCx company, Zibrio, was up for an award in the 2019 SXSW Pitch event, but left the contest empty handed.

TMCx has multiple representatives at the festival, and the organization partnered with Energizing Health to host events throughout the first weekend of the conference.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.

New Texas Stock Exchange officially begins trading in Dallas

Welcome to Y'all Street

Two-step aside, New York Stock Exchange and Nasdaq. The Dallas-based Texas Stock Exchange, nicknamed Y’all Street, just kicked off live trading with five stocks — and lots of Lone Star ambition.

“The Texas Stock Exchange aims to revitalize competition for [stock] issuers, establish the premier venue for listings, and create a world-class trading platform for all market participants,” the exchange says in a fact sheet.

The exchange — whose Texas-influenced nickname is a nod to New York City’s Wall Street — has collected at least $275 million in investments. The roughly 90 financial backers of TXSE include Bank of America, BlackRock, Charles Schwab, Citadel Securities, Dell Family Office, Fortress, Goldman Sachs, and JPMorgan Chase.

Representatives of TXSE couldn’t be reached for comment. On its website, the exchange calls itself “the most well-capitalized equities exchange to ever be approved” by the U.S. Securities and Exchange Commission (SEC).

Not to be outdone, NYSE has launched Dallas-based NYSE Texas and Nasdaq has expanded its presence in Dallas.

Y’all Street adds to Dallas-Fort Worth’s rising status as a major hub for financial services, with The Wall Street Journal naming North Texas the country’s second biggest financial hub after New York City.

“A homegrown national exchange means more jobs, more investment, and more growth opportunities for businesses and communities across the Lone Star State,” Gabriela von zur Muehlen, senior vice president and chief policy officer at the Texas Association of Business, told The Texas Tribune.

Bulent Temel, an associate professor of practice in economics at the University of Texas at San Antonio, told Texas Standard that TXSE “is going to boost the credibility of the Texas economy.”

Texas’ estimated gross domestic product (GDP), a yardstick for the size of an economy, climbed to a record-setting $2.9 trillion in 2025, making it the state with the second highest GDP after California. DFW’s estimated GDP in 2023 stood at $744.6 billion, eclipsing the GDP of many countries.

“The center of gravity for American capitalism is now headquartered in the Boom Belt,” Abbott proclaimed in April, referring to an 11-state region (including Texas) in the South and Southeast that’s seeing tremendous economic and population growth. “The Texas Stock Exchange is the natural extension of that capitalism. It ensures that capital markets will reflect the quadrant that is driving American growth.”

---

This article originally appeared on CultureMap.com.

Orion vehicle manager reflects on Artemis II, looks to 2028 moon mission

Q&A

Humanity is finally headed back to the moon after more than half a century. This year's launch of the Artemis II mission in the Orion spacecraft put four crew members in lunar orbit and tested the new ship developed by Lockheed Martin.

Everything went smoothly, safely returning astronauts home, but there is always room to improve. InnovationMap chatted via email with Orion vehicle manager Branelle Rodriguez, shortly after a talk at The Ion, for insight on how Orion might perform in the future as the next lunar landing approaches in early 2028.

InnovationMap: How satisfied are you with the way Orion operated on this past mission?

Branelle Rodriguez: Orion performed exceptionally well during Artemis II, successfully demonstrating critical spacecraft capabilities, including life support systems, displays and controls, and executing manual piloting operations. Artemis II brought humans back to the moon, achieving key exploration and scientific imagery, while validating systems essential for future Artemis missions.

IM: What is the most important thing you learned about improving Orion for the next mission?

BR: The Artemis II mission provided invaluable insights into crew operations and spacecraft performance in a deep-space environment. With every mission, NASA applies lessons learned to continuously improve Orion’s operations, validate design and ensure mission readiness. Artemis II offered our first opportunity to evaluate several new systems and gain a deeper understanding of what it is like for astronauts to live and work inside the spacecraft. The operational, technical and human factors data collected are being integrated across the program to refine future missions, reduce risk and enhance overall mission success.

IM: How has Orion helped the mission to explore space?

BR: Orion is one of NASA’s foundational elements for human deep space exploration—not only supporting the mission but serving as a core component of it. It is currently the only spacecraft capable of carrying crew on deep space missions and returning them safely to Earth from the high speeds required from the vicinity of the moon. No other spacecraft has the technology to endure the extremes that come with human deep-space travel, such as advanced environmental and life support, navigation, communications, radiation shielding, and the world’s largest ablative heat shield to protect the astronauts during reentry into Earth’s atmosphere. Orion has already taken astronauts to explore space farther than ever before—252,756 miles from Earth— and will carry crews to the moon on future missions to explore the lunar South Pole region. The astronauts’ observations, samples, and data collected on these future missions will expand our understanding of our solar system and home planet.

---

This conversation has been edited for brevity and clarity.

View All Listings